NCT03854110 - Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Pancreatic Cancer, Adult

Interventions

DRUG

GP-2250

GP-2250 monotherapy for pharmacokinetics and safety; GP-2250 plus gemcitabine for safety, tolerability, pharmacokinetics, and biomarker assessments

Trial Locations (5)

Abramson Cancer Center at the University of Pennsylvania, Phildelphia

Wake Forest Baptist Health, Winston-Salem

University of Kansas Cancer Center, Fairway

Hoag Family Cancer Institute, Newport Beach

Beth Israel Deaconess Medical Center, Boston